CERO Therapeutics Holdings, Inc. announced significant changes to its executive leadership on September 25, 2024. Brian Atwood stepped down as President and CEO, with Vice Chairman Chris Ehrlich assuming the role of Chairman and Interim Chief Executive Officer. Additionally, Charles Carter, the Chief Financial Officer, and Daniel Corey, M.D., the Chief Technology Officer, also elected to step down from their positions.
The company also disclosed that its Investigational New Drug (IND) Application for CER-1236 is currently on clinical hold. This hold is related to two pharmacology and toxicology questions, which CERO Therapeutics believes can be addressed. The company has requested a Type A Meeting with the U.S. Food and Drug Administration (FDA) to discuss its plans and data collected to date.
In conjunction with these developments, CERO Therapeutics secured a financing commitment of $1.25 million from existing investors. These funds are intended to support the company's efforts to resolve the IND issue for CER-1236 and minimize capital needs through cost reductions. The company has initiated preclinical in vitro studies and experiments to address the FDA's questions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.